Skip to search formSkip to main contentSkip to account menu

HBY 097

Known as: HBY-097 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Quinoxalines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations.
Clinically relevant Lys103Asn (K103N) mutant frequently observed in HIV-1 reverse transcriptase (RT) confers drug resistance. To… 
Highly Cited
1998
Highly Cited
1998
Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride
ABSTRACT Human immunodeficiency virus type 1 (HIV-1) strains resistant to nonnucleoside reverse transcriptase inhibitors (NNRTIs… 
1998
1998
Quantitative analysis of HBY 097 and its metabolites in human serum and urine by HPLC.
Highly Cited
1995
Highly Cited
1995
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication
HBY 097 [(S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3, 4-dihydroquinoxaline-2(1H)-thione] was selected from a series… 
1995
1995
Los Angeles, New York, Stanford University: HBY 097, new drug may weaken HIV.
A three-month human trial will be conducted in Los Angeles, New York, and San Francisco, to test a new drug, HBY 097. In… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)